Evidence map›Paper›PMID 40843362›Full record

ArticleCancer drug resistance (Alhambra, Calif.)2025

Effects of FAP

Jing Wu, Peng-Fei Zhang, Yu Zeng, Ya-Nan Hai, Kun-Ming Zhang, Shu Dong, Ji-Chong Xu, Lan-Lin Zhang, Zhi-Xiong Wu, Hong Jiang

Abstract read
In one paragraph

Article in Cancer drug resistance (Alhambra, Calif.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jing WuDepartment of Cancer Center, Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, China.
Peng-Fei ZhangDepartment of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Yu ZengDepartment of Pathology, Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, China.
Ya-Nan HaiDepartment of Oncology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, China.
Kun-Ming ZhangDepartment of Oncology, People's Hospital of Longhua, Shenzhen 518109, Guangdong, China.
Shu DongDepartment of Integrative Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Ji-Chong XuDepartment of Interventional Radiology, Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, China.
Lan-Lin ZhangDepartment of Cancer Center, Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, China.
Zhi-Xiong WuDepartment of Cancer Center, Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, China.
Hong JiangDepartment of Cancer Center, Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

anti-PD-1 therapyCancer-associated fibroblastsimmune evasionnaive CD4+ T cell differentiation

Identifiers

PMID40843362
PMCPMC12366491

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.